0000899243-22-032687.txt : 20221004
0000899243-22-032687.hdr.sgml : 20221004
20221004170023
ACCESSION NUMBER: 0000899243-22-032687
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221001
FILED AS OF DATE: 20221004
DATE AS OF CHANGE: 20221004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Habibizad Nazila
CENTRAL INDEX KEY: 0001913961
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37539
FILM NUMBER: 221292735
MAIL ADDRESS:
STREET 1: C/O GLOBAL BLOOD THERAPEUTICS, INC.
STREET 2: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Global Blood Therapeutics, Inc.
CENTRAL INDEX KEY: 0001629137
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 274825712
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650741-7700
MAIL ADDRESS:
STREET 1: 181 OYSTER POINT BLVD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-10-01
0
0001629137
Global Blood Therapeutics, Inc.
GBT
0001913961
Habibizad Nazila
C/O GLOBAL BLOOD THERAPEUTICS, INC.
181 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
See Remarks
Common Stock
2022-09-29
5
G
0
E
3500
0.00
D
38123
D
Common Stock
2022-10-01
4
M
0
1375
A
39498
D
Common Stock
2022-10-01
4
M
0
182
A
39680
D
Restricted Stock Units
2022-10-01
4
M
0
1375
0.00
D
Common Stock
1375
2750
D
Restricted Stock Units
2022-10-01
4
M
0
182
0.00
D
Common Stock
182
548
D
Each Restricted Stock Unit ("RSU") represents the right to receive one share of the Issuer's Common Stock.
The shares of Common Stock underlying the original grant of 11,000 RSUs vest in eight semi-annual installments after October 1, 2019 through October 1, 2023, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
The shares of Common Stock underlying the original grant of 1,461 RSUs vest in eight semi-annual installments after April 1, 2020 through April 1, 2024, subject to the Reporting Person's continuous service with the Issuer through each vesting date, and have no expiration date. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Executive Vice President, Operations
/s/ Miguel Carrillo, Attorney-in-Fact
2022-10-04